Novartis generic anaemia drug on sale in weeks-FT

Tue Sep 11, 2007 2:02am EDT

ZURICH, Sept 11 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) expects its cut-price version of the anaemia drug epoetin alfa, or EPO, to go on sale in the UK and Germany in coming weeks, the Financial Times reported on Tuesday.

Andreas Rummelt, head of Novartis' Sandoz generics unit, said the drug was likely to be priced about 25 percent to 30 percent cheaper than the original medicine, the FT wrote.

The drug was granted European approval at the end of August.

((Reporting by Katie Reid, editing by Rory Channing; e-mail: katie.reid@reuters.com; Reuters Messaging: katie.reid.reuters.com@reuters.net; telephone: +41 (0) 44 631 7320)) Keywords: NOVARTIS EPO/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL1198175

Related Quotes and News

Company
Price
Related News
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.